Growth hormone and testosterone in heart failure therapy

Bibliography

• Hunt SA, Abraham WT, Chin MH, ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235
   PubMed Web of Science ®Google Scholar
• Levy D, Kenchaiah S, Larson MG, Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones RD, Jones TH, Channer KS. Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail 2002;4:673-80
   PubMedGoogle Scholar
• Anker SD, Chua TP, Ponikowski P, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34
   PubMed Web of Science ®Google Scholar
• Chaggar PS, Malkin CJ, Shaw SM, Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. Cardiovasc Ther Fall 2009;27:187-93
   PubMed Web of Science ®Google Scholar
• von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227-52
   PubMed Web of Science ®Google Scholar
• Anker SD, Clark AL, Kemp M, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997;30:997-1001
   PubMed Web of Science ®Google Scholar
• Niebauer J, Pflaum CD, Clark AL, Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998;32:393-7
   PubMed Web of Science ®Google Scholar
• Kontoleon P, Anastasiou-Nana M, Papapetrou P, Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003;87:179-83
   PubMed Web of Science ®Google Scholar
• Perrot A, Ranke MB, Dietz R, Osterziel KJ. Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001;16:127-31
   PubMed Web of Science ®Google Scholar
• Climent V, Marin F, Pico A. Pharmacologic therapy in growth hormone disorders and the heart. Curr Med Chem 2007;14:1399-407
   PubMedGoogle Scholar
• Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 2008;69:347-58
   PubMed Web of Science ®Google Scholar
• Sacca L. Growth hormone: a newcomer in cardiovascular medicine. Cardiovasc Res 1997;36:3-9
   PubMedGoogle Scholar
• Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992;19:25-32
   PubMed Web of Science ®Google Scholar
• Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995;30:825-34
   PubMed Web of Science ®Google Scholar
• Guse A, Kiess W, Funk B, Identification and characterization of insulin-like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1, 4, 5-trisphosphate formation. Endocrinology 1992;130:145-51
   PubMedGoogle Scholar
• Mathews L, Enberg B, Norstedt G. Regulation of rat growth hormone receptor gene expression. J Biol Chem 1989;264:9905-10
   PubMedGoogle Scholar
• Ito H, Hiroe M, Hirata Y, Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993;87:1715-21
   PubMed Web of Science ®Google Scholar
• Chen DB, Wang L, Wang PH. Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes. Life Sci 2000;67:1683-93
   PubMed Web of Science ®Google Scholar
• Cittadini A, Ishiguro Y, Stromer H, Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 1998;83:50-9
   PubMed Web of Science ®Google Scholar
• Tsukahara H, Gordienko D, Tonshoff B, Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994;45:598-604
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Conover C, Schwartz R. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res 2000;86:125-30
   PubMed Web of Science ®Google Scholar
• Cittadini A, Saldamarco L, Marra AM, Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009;94:3329-36
   PubMedGoogle Scholar
• Osterziel KJ, Blum WF, Strohm O, Dietz R. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J Clin Endocrinol Metab 2000;85:1533-9
   PubMed Web of Science ®Google Scholar
• Anker SD, Volterrani M, Pflaum CD, Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001;38:443-52
   PubMed Web of Science ®Google Scholar
• Petretta M, Colao A, Sardu C, NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007;17:288-96
   PubMed Web of Science ®Google Scholar
• Lund LH, Freda P, Williams JJ, Growth hormone resistance in severe heart failure resolves after cardiac transplantation. Eur J Heart Fail 2009;11:525-8
   PubMed Web of Science ®Google Scholar
• Anker SD, Negassa A, Coats AJS, Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83
   PubMed Web of Science ®Google Scholar
• Delafontaine P, Brink M. The growth hormone and insulin-like growth factor 1 axis in heart failure. Ann Endocrinol (Paris) 2000;61:22-6
   PubMedGoogle Scholar
• Osterziel KJ, Ranke MB, Strohm O, Dietz R. The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol 2000;53:61-8
   PubMedGoogle Scholar
• Sacca L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail 2009;2:151-6
   PubMed Web of Science ®Google Scholar
• Richardson P, McKenna W, Bristow M, Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2
   PubMed Web of Science ®Google Scholar
• Abelmann WH. Classification and natural history of primary myocardial disease. Prog Cardiovasc Dis 1984;27:73-94
   PubMed Web of Science ®Google Scholar
• Komajda M, Charron P. Idiopathic cardiomyopathies. Rev Prat 2002;52:1664-70
   PubMedGoogle Scholar
• Mulumba M, Cemeus C, Dumont L, Recombinant bovine growth hormone-induced reduction of atrial natriuretic peptide is associated with improved left ventricular contractility and reverse remodeling in cardiomyopathic UM-X7.1 hamsters with congestive heart failure. Growth Horm IGF Res 2007;17:96-103
   PubMedGoogle Scholar
• Fazio S, Sabatini D, Capaldo B, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-14
   PubMed Web of Science ®Google Scholar
• Cittadini A, Stromer H, Katz S, Differential cardiac effects of growth hormone and insulin-like growth factor1 in the rat: a combined in vivo and in vitro evaluation. Circulation 1996;93:800-9
   PubMed Web of Science ®Google Scholar
• Jose VJ, Zechariah TU, George P, Jonathan V. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J 1999;51:183-5
   PubMedGoogle Scholar
• Osterziel KJ, Strohm O, Schuler J, Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:1233-7
   PubMed Web of Science ®Google Scholar
• Napoli R, Guardasole V, Matarazzo M, Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002;39:90-5
   PubMed Web of Science ®Google Scholar
• Le Corvoisier P, Hittinger L, Chanson P, Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 2007;92:180-5
   PubMedGoogle Scholar
• Drexler H, Hayoz D, Münzel T, Endothelial function in congestive heart failure. Am Heart J 1993;126:761-4
   PubMedGoogle Scholar
• Napoli R, Guardasole V, Angelini V, Acute effects of growth hormone on vascular function in human subjects. J Clin Endocrinol Metab 2003;88:2817-20
   PubMedGoogle Scholar
• Volterrani M, Desenzani P, Lorusso R, Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997;349:1067-8
   PubMed Web of Science ®Google Scholar
• Napoli R, Guardasole V, Matarazzo M, Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002;39:90-5
   PubMed Web of Science ®Google Scholar
• Isgaard J, Kujacic V, Jennische E, Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997;27:517-25
   PubMedGoogle Scholar
• Tajima M, Weinberg E, Bartunek J, Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 1999;99:127-34
   PubMed Web of Science ®Google Scholar
• Timsit J, Riou B, Bertherat J, Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 1990;86:507-15
   PubMed Web of Science ®Google Scholar
• Henry L. Left ventricular systolic dysfunction and ischemic cardiomyopathy. Crit Care Nurs Q 2003;26:16-21
   PubMedGoogle Scholar
• Delahaye F, de Gevigney G. Epidemiology and natural history of cardiac failure. Rev Prat 1997;47:2114-7
   PubMedGoogle Scholar
• Jayasankar V, Pirolli TJ, Bish LT, Targeted overexpression of growth hormone by adenoviral gene transfer preserves myocardial function and ventricular geometry in ischemic cardiomyopathy. J Mol Cell Cardiol 2004;36:531-8
   PubMed Web of Science ®Google Scholar
• Follath F. Ischemic versus non-ischemic heart failure: should the etiology be determined? Heart Fail Monit 2001;1:122-5
   PubMedGoogle Scholar
• Genth-Zotz S, Zotz R, Geil S, Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 1999;99:18-21
   PubMed Web of Science ®Google Scholar
• Parissis JT, Adamopoulos S, Karatzas D, Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. Eur J Cardiovasc Prev Rehabil 2005;12:164-8
   PubMedGoogle Scholar
• Cittadini A, Isgaard J, Monti MG, Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003;41:2154-63
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Lu H, Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res 2002;12:208-15
   PubMed Web of Science ®Google Scholar
• Seiva FR, Ebaid GM, Castro AV, Growth hormone and heart failure: oxidative stress and energetic metabolism in rats. Growth Horm IGF Res 2008;18:275-83
   PubMed Web of Science ®Google Scholar
• Adamopoulos S, Parissis JT, Paraskevaidis I, Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2003;24:2186-96
   PubMed Web of Science ®Google Scholar
• Adamopoulos S, Parissis JT, Georgiadis M, Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 2002;144:359-64
   PubMed Web of Science ®Google Scholar
• Smit JW, Janssen YJ, Lamb HJ, Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab 2001;86:4638-43
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Smit JW, de Roos A, Six-months of recombinant human GH therapy in patients with ischemic cardiac failure. Int J Cardiovasc Imaging 2004;20:53-60
   PubMed Web of Science ®Google Scholar
• Spallarossa P, Rossettin P, Minuto F, Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am J Cardiol 1999;84:430-3
   PubMed Web of Science ®Google Scholar
• Isgaard J, Bergh CH, Caidahl K, A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998;19:1704-11
   PubMed Web of Science ®Google Scholar
• Fazio S, Palmieri EA, Affuso F, Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 2007;92:4218-23
   PubMedGoogle Scholar
• Demers C, McKelvie RS. Growth hormone therapy in heart failure: a novel therapy worthy of further consideration? Expert Opin Investig Drugs 2005;14:1009-18
   PubMed Web of Science ®Google Scholar
• Bocchi EA, Massuda Z, Guilherme G, Growth hormone for optimization of refractory heart failure treatment. Arq Bras Cardiol 1999;73:391-8
   PubMedGoogle Scholar
• Bocchi E, Moura L, Guimaraes G, Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol 2006;110:313-17
   PubMedGoogle Scholar
• Fukuda I, Hizuka N, Murakami Y, Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 2001;40:987-92
   PubMedGoogle Scholar
• Sullivan D, Carter W, Warr W, Williams L. Side effects resulting from the use of growth hormone and insulin-like growth factor-I as combined therapy to frail elderly patients. J Gerontol A Biol Sci Med Sci 1998;53:M183-7
   Google Scholar
• Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003;87:179-83
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, West JN, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64
   PubMed Web of Science ®Google Scholar
• Aukrust P, Ueland T, Gullestad L, Yndestad A. Testosterone: a novel therapeutic approach in chronic heart failure? J Am Coll Cardiol 2009;54:928-9
   PubMedGoogle Scholar
• Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009;5:427-48
   PubMedGoogle Scholar
• Jankowska EA, Biel B, Majda J, Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829-37
   PubMed Web of Science ®Google Scholar
• Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 2009;5:113-21
   PubMedGoogle Scholar
• Yeap BB, Wilce JA, Leedman PJ. The androgen receptor mRNA. Bioessays 2004;26:672-82
   PubMed Web of Science ®Google Scholar
• Rahman F, Christian HC. Non-classical actions of testosterone: an update. Trends Endocrinol Metab 2007;18:371-8
   PubMed Web of Science ®Google Scholar
• Jones RD, Pugh PJ, Jones TH, Channer KS. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol 2003;138:733-44
   PubMed Web of Science ®Google Scholar
• Scragg JL, Dallas ML, Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium 2007;42:11-5
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Jones RD, Jones TH, Channer KS. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) 2006;111:265-74
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909-15
   PubMed Web of Science ®Google Scholar
• Webb CM, McNeill JG, Hayward CS, Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100:1690-6
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906-11
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-6
   PubMed Web of Science ®Google Scholar
• Cornoldi A, Caminiti G, Marazzi G, Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol 2009. [Epub ahead of print]
   Google Scholar
• Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol 1999;83:123-5, A129
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones RD, West JN, Testosterone treatment for men with chronic heart failure. Heart 2004;90:446-7
   PubMed Web of Science ®Google Scholar
• Morales FJ, Martinez A, Mendez M, A shuttle walk test for assessment of functional capacity in chronic heart failure. Am Heart J 1999;138:291-8
   PubMed Web of Science ®Google Scholar
• Morales FJ, Montemayor T, Martinez A. Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure. Int J Cardiol 2000;76:101-5
   PubMed Web of Science ®Google Scholar
• Caminiti G, Volterrani M, Iellamo F, Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27
   PubMed Web of Science ®Google Scholar
• Arena R, Myers J, Abella J, Development of a ventilatory classification system in patients with heart failure. Circulation 2007;115:2410-17
   PubMed Web of Science ®Google Scholar
• El-Mas MM, Afify EA, Mohy El-Din MM, Testosterone facilitates the baroreceptor control of reflex bradycardia: role of cardiac sympathetic and parasympathetic components. J Cardiovasc Pharmacol 2001;38:754-63
   PubMed Web of Science ®Google Scholar
• Mortara A, La Rovere MT, Pinna GD, Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997;96:3450-8
   PubMed Web of Science ®Google Scholar
• Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med 2007;120:835-40
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010
   PubMed Web of Science ®Google Scholar
• Toogood A, Jones J, O'Neill P, The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol 1998;48:569-76
   PubMedGoogle Scholar